ArticleRespiratory research2021
NT-pro BNP in AECOPD-PH: old biomarker, new insights-based on a large retrospective case-controlled study.
Article in Respiratory research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.
- Red cell distribution width related to the severity of the disease in patients with AECOPD.Biomarkers in medicine · 2025Pooled it
- NT-proBNP in Different Patient Groups of COPD: A Systematic Review and Meta-Analysis.International journal of chronic obstructive pulmonary disease · 2023Pooled it
- Respiratory Biomarkers: An Opportunity for Patient-Centric Microsampling Approach for Treatment Optimization.Clinical and translational science · 2026Review
- Unveiling MicroRNA-21 as a non-invasive diagnostic biomarker in chronic obstructive pulmonary disease-associated pulmonary hypertension: Comparative insights with NT-proBNP.Lung India : official organ of Indian Chest Society · 2026Article
- Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension: A Comparative Study of Biomarkers and Clinical Indicators.Pulmonary circulation · 2026Article
- From China's Multicenter Prospective Cohort: Right Ventricular Afterload and Prognosis in Hospitalized Patients with Acute Exacerbation of COPD.International journal of chronic obstructive pulmonary disease · 2026Article
- Performance of Guideline-Recommended Approaches to Echocardiographic Investigation for Pulmonary Hypertension: Analysis of the CIPHER Study.Pulmonary circulation · 2026Article
- Association between red cell distribution width-to-albumin ratio and In-hospital mortality in patients with acute exacerbation of chronic obstructive pulmonary disease and respiratory failure: a retrospective cohort study.Biomarkers in medicine · 2025Article
- Development and validation of the machine learning model for acute exacerbation of chronic obstructive pulmonary disease prediction based on inflammatory biomarkers.Frontiers in medicine · 2025Article
- Pulmonary hypertension associated with lung diseases.The European respiratory journal · 2024Review
- Diagnostic Value of Galectin-3 in Exacerbations of Chronic Obstructive Pulmonary Disease.Medicina (Kaunas, Lithuania) · 2024Article
- Article
- Natriuretic Peptides as Biomarkers: Narrative Review and Considerations in Cardiovascular and Respiratory Dysfunctions.The Yale journal of biology and medicine · 2023Review
- The Emerging Clinical Significance of the Red Cell Distribution Width as a Biomarker in Chronic Obstructive Pulmonary Disease: A Systematic Review.Journal of clinical medicine · 2022Review
- Emerging phenotypes of pulmonary hypertension associated with COPD: a field guide.Current opinion in pulmonary medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundPulmonary hypertension (PH) is one of the common complications in chronic obstructive pulmonary disease (COPD). The study aimed to evaluate the predicting ability of N-terminal pro brain natriuretic peptide (NT-pro BNP) in patients with AECOPD-PH and its relationship with the severity of PH.
methodsA large retrospective case-controlled study (n = 1072) was performed in the First Affiliated Hospital of Xinjiang Medical University from January 2018 to December 2020, and patients were divided into stable COPD (n = 178), AECOPD (n = 688) and AECOPD-PH group (n = 206). Different statistical models were used to screen for reliable and stable biomarkers.
resultsIn unadjusted analysis and PSM (model 1, 2, 3), red cell distribution width (RDW), total bilirubin (TBIL), and NT-pro BNP were higher in patients with AECOPD-PH than those in AECOPD group. Logistic regression analysis showed, when the range of NT-proBNP was 271-1165 pg/mL (OR: 0.293; 95%CI: 0.184-0.467; P < 0.001) and NT-proBNP > 1165 pg/mL (OR: 0.559; 95%CI: 0.338-0.926; P = 0.024), the morbidity risk of PH in AECOPD patients was increased, so did TBIL. In receiver operating characteristic (ROC) curves, at the cut-off value of NT-proBNP was 175.14 pg/mL, AUC was 0.651 (P < 0.001), which was better than TBIL (AUC: 0.590, P < 0.001). As for the results of rank correlation analysis, NT-proBNP had a weak correlation with severity of PH with AECOPD (r
conclusionsOur findings suggest that NT-proBNP has a diagnostic efficacy in AECOPD-PH and NT-proBNP has a weak correlation with severity of PH with AECOPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.